Case Control Study
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Mar 7, 2020; 26(9): 933-946
Published online Mar 7, 2020. doi: 10.3748/wjg.v26.i9.933
Exosomal miR-182 regulates the effect of RECK on gallbladder cancer
Hong Zheng, Jin-Jing Wang, Li-Jin Zhao, Xiao-Rong Yang, Yong-Lin Yu
Hong Zheng, Jin-Jing Wang, Xiao-Rong Yang, Yong-Lin Yu, Department of Pathology, Affiliated Hospital of Zunyi Medical University, Zunyi 563003, Guizhou Province, China
Li-Jin Zhao, Department of Hepatopancreatobiliary Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi 563003, Guizhou Province, China
Author contributions: Zheng H performed the majority of the experiments and analyzed the data; Wang JJ performed the molecular investigations; Zhao LJ designed and coordinated the research; Yang XR and Yu YL wrote the paper.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of Affiliated Hospital of Zunyi Medical University.
Informed consent statement: All patients in our study provided informed consent.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Hong Zheng, MD, Chief Physician, Department of Pathology, Affiliated Hospital of Zunyi Medical University, No. 149 Dalian Road, Huichuan District, Zunyi 563003, Guizhou Province, China.
Received: December 5, 2019
Peer-review started: December 5, 2019
First decision: December 30, 2019
Revised: January 8, 2020
Accepted: January 19, 2020
Article in press: January 19, 2020
Published online: March 7, 2020
Processing time: 92 Days and 0.4 Hours
Research background

As the most common biliary malignancy, GC is an elderly-biased disease. Although extensive studies have elucidated the molecular mechanism of miR-182 and RECK in various cancers, the specific roles of exosomal miR-182 and RECK in GC remain poorly understood.

Research motivation

The expression of miR-182 and exosomal miR-182 was increased in gallbladder cancer, while RECK decreased. Targetscan7.2 predicted RECK could bind with miR-182 via 3’UTR. RECK was negatively correlated with miR-182.

Research objectives

This study was set out to explore the relationship between exosomal miR-182/RECK and metastasis of GC.

Research methods

Paired GC and adjacent normal tissues were collected from 78 patients. qPCR was employed to detect miR-182 and exosomal miR-182 expression, and Western blot was adopted to determine RECK expression. In addition, the effect of exosomal miR-182/RECK on the biological function of human GC cells were observed. Moreover, double luciferase reporter gene assay was applied to validate the targeting relationship between miR-182 and RECK.

Research results

Compared with normal gallbladder epithelial cells, miR-182 was highly expressed in GC cells, while RECK was lowly expressed. Exosomal miR-182 could be absorbed and transferred by cells. Exosomal miR-182 inhibited RECK expression and promoted migration and invasion of GC cells.

Research conclusions

Exosomal miR-182 can significantly promote the migration and invasion of GC cells by inhibiting RECK, and thus miR-182 can be used as a therapeutic target for GC.

Research perspectives

The signaling pathways implicated in miR-182/RECK should be explored in future experimental design to supplement the oncogenic network of exosomal miR-182. The clinical value of exosomal miR-182 in GC remains to be discussed.